Abstract:Background: Cardiovascular disease, including acute coronary syndromes (ACS) comprising ST-elevation and non-ST-elevation myocardial infarction (STEMI/NSTEMI) and unstable angina (UA), remains the leading cause of death in the United States. The direct and indirect costs of cardiovascular disease are estimated to surpass $165 billion in 2009. Antiplatelet pharmacotherapy has been shown to reduce ACS-related death and is part of the American College of Chest Physicians (ACCP) and the American College of Cardiology /American Heart Association (ACC/AHA) treatment guideline recommendations. Objective: To provide formulary decision makers with information on the pharmacokinetics and pharmacodynamics of the thienopyridine antiplatelet agent prasugrel as well as an analysis of available efficacy and safety data and its risk-benefit profile in comparison with clopidogrel. Methods: Literature search for information on prasugrel with a focus on (a) the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial, (b) briefing documents from the FDA available as of March 1, 2009, and (c) ongoing phase III studies of prasugrel. Results: TRITON-TIMI 38 was a double blind, randomized superiority study involving 13,608 patients with moderate-to high-risk acute coronary syndromes with scheduled percutaneous coronary intervention (PCI). TRITON-TIMI 38 data were available in a published manuscript and in an FDA review. Study patients were randomized to either prasugrel or clopidogrel once daily. The primary end point (composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 643 patients (9.9%) in the prasugrel group and 781 patients (12.1%) in the clopidogrel group (HR = 0.82, 95% CI = 0.73-0.93, P = 0.002). Non-coronary artery bypass graft (non-CABG) TIMI major hemorrhage occurred in 146 patients (2.4%) in the prasugrel group compared with 111 patients (1.8%) in the clopidogrel group (HR=1.32, 95% CI=1.03-1.68, P = 0.03). A subanalysis of the TRITON-TIMI 38 trial data revealed a net harm for patients with a prior history of stroke or transient ischemic attack (TIA) when treated with prasugrel (HR = 1.54, 95% CI = 1.02-2.32, P = 0.04). Combination prasugrel and aspirin is currently being studied in comparison with clopidogrel and aspirin for the treatment of UA/NSTEMI patients that are medically managed. Conclusions: For every 1,000 patients treated with prasugrel instead of clopidogrel, a total of 24 end points would be prevented at the cost of 10 additional bleeding events. On February 3, 2009, the FDA Cardiovascular and Renal Drugs Advisory Committee deemed this to be an acceptable riskbenefit profile. The committee recommended a label contraindication for patients with prior history of transient ischemic attack or stroke. Treatment versus time analyses demonstrated both early and sustained benefit for prasugrel compared with clopidogrel. However, prasugrel was associated with fewer cardiovascular events prevented per bleeding case the longer the duration of therapy. The study population of TRITON-TIMI 38 was limited to patients undergoing PCI. Managed care decision makers should consider specific criteria limiting prasugrel use to health plan members with characteristics similar to the study population in TRITON-TIMI 38 that benefited from treatment and avoiding use in patients with prior history of stroke or TIA. More data are needed before prasugrel can be recommended in patient groups not addressed by TRITON-TIMI 38.

Prehospital crushed versus integral prasugrel loading dose in STEMI patients with a large myocardial area

Effects of Intracoronary administration of nitroprusside on no-reflow phenomenon during emergency percutaneous coronary Intervention in patients with acute myocardial infarction

Single Bolus r-SAK Before Primary PCI for ST-Segment–Elevation Myocardial Infarction

Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Post-dilatation Improves Stent Apposition in Patients with ST-segment Elevation Myocardial Infarction Receiving Primary Percutaneous Intervention: A Multicenter, Randomized Controlled Trial Using Optical Coherence Tomography.

Pretransfer Aspirin Administration and Its Impact on Angiographic Outcomes for Patients with ST-Elevation Myocardial Infarction

Current and Future Roles of Glycoprotein IIb–IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction

A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI

A Randomized Trial of Deferred Stenting Versus Immediate Stenting to Prevent No- or Slow-Reflow in Acute ST-Segment Elevation Myocardial Infarction (DEFER-STEMI)

Efficacy and Safety of a Pharmaco-Invasive Strategy with Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment–Elevation Myocardial Infarction

Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes

Impact of high loading-dose atorvastatin pre-treatment before primary percutaneous coronary intervention on coronary flow in patients with ST segment elevation myocardial infarction

Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial

Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction

Pretreatment With P2Y12 Inhibitors in ST-Segment Elevation Myocardial Infarction

Critical review of prasugrel for formulary decision makers

Sonothrombolysis in Patients With ST-Elevation Myocardial Infarction With Electrocardiographic No-Reflow After Percutaneous Coronary Intervention: A Randomized Controlled Trial

Upstream Vs Deferred Administration of Small-Molecule Glycoprotein Iib/Iiia Inhibitors in Primary Percutaneous Coronary Intervention for St-Segment Elevation Myocardial Infarction - Insights from Randomized Clinical Trials

Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk

Short-term Outcomes of High Loading Dose Clopidogrel Pretreatment Before Coronary Stenting in Patients with Acute Coronary Syndromes

Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel